UNCLASSIFIED

AD NUMBER

ADB232955

NEW LIMITATION CHANGE

TO

Approved for public release, distribution unlimited

FROM

Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; Oct 97. Other requests shall be referred to US Army Medical Reserch and Materiel Comd., Fort Detrick, MD 21702-5012.

AUTHORITY

U.S. Army Medical Research and Materiel Command ltr., dtd July 23, 2001.

THIS PAGE IS UNCLASSIFIED

AD_____

GRANT NUMBER DAMD17-96-1-6113

TITLE: Inducible Transgenic Models of BRCA1 Function

PRINCIPAL INVESTIGATOR: Lewis A. Chodosh, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Pennsylvania
Philadelphia, Pennsylvania 19104-3246

REPORT DATE: October 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Oct 97). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19980130 153

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY *(Leave blank)*	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED
	October 1997	Annual (15 Sep 96 - 14 Sep 97)

4. TITLE AND SUBTITLE

Inducible Transgenic Models of BRCA1 Function

5. FUNDING NUMBERS

DAMD17-96-1-6113

6. AUTHOR(S)

Chodosh, Lewis A., M.D., Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

University of Pennsylvania
Philadelphia, Pennsylvania 19104-3246

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT

Distribution authorized to U.S. Government agencies only (proprietary information, Oct 97). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

12b. DISTRIBUTION CODE

DTIC QUALITY INSPECTED 2

13. ABSTRACT *(Maximum 200 words)*

Germline mutations in the breast and ovarian cancer susceptibility gene, *BRCA1*, account for a large proportion of families with inherited breast and ovarian cancer. Interestingly, while germline *BRCA1* mutations predispose carriers to adenocarcinoma of the breast, no somatic *BRCA1* mutations have been found in sporadic primary breast cancers. This observation suggests that this molecule may normally protect the breast against carcinogenesis only during specific stages of mammary gland development. Previously, we have analyzed the temporal and spatial pattern of *Brca1* expression during normal mouse embryogenesis, in adult tissues, and during postnatal mammary gland development. These studies support a role for *Brca1* in the regulation of cell proliferation and differentiation in the breast during puberty and pregnancy. We hypothesize that *Brca1* plays a critical role in mammary gland development, and that its function is temporally restricted to particular developmental phases. In this application, we propose to test this hypothesis by using a modified tetracycline-inducible expression system to either induce or abolish *Brca1* expression in transgenic mice during particular developmental stages in a temporally-restricted and breast-specific manner. Through this approach, we hope to understand more clearly how the loss or mutation of this molecule contributes to carcinogenesis in a developmental-specific manner.

14. SUBJECT TERMS	15. NUMBER OF PAGES
Breast Cancer; BRCA1; Mammary Gland Development; Tumor Suppressor Genes; Transgenic Animals	15
	16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Limited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

LAC Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

LAC In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

LAC In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

LAC In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Lewis L. Elwood MD PhD 10/10/97

PI - Signature Date

TABLE OF CONTENTS

INTRODUCTION

Genetic analysis of families in which multiple individuals have developed breast cancer suggests that 5-10% of breast cancer cases result from the inheritance of germline mutations in autosomal dominant susceptibility genes[1, 2]. Germline mutations in one of these breast cancer susceptibility genes, *BRCA1*, appear to account for most families with inherited breast and ovarian cancer, and somewhat less than half of families displaying inherited breast cancer alone[3, 4]. The *BRCA1* gene encodes a 220 kDa phosphoprotein that contains a RING finger motif, a transcriptional activation domain, and a BRCT domain typically found in proteins involved in cell cycle regulation and DNA damage response[4-10]. Tumors arising in patients with germline *BRCA1* mutations almost invariably display loss of the wild-type *BRCA1* allele, suggesting that *BRCA1* is a tumor suppressor gene[11]. Taken together with findings that reduction in *BRCA1* expression *in vitro* results in accelerated growth of breast and ovarian cancer cell lines, and that overexpression of *BRCA1* results in inhibited growth of such cell lines, these observations are consistent with a model in which *BRCA1* negatively regulates proliferation in adult tissues[12-14]. Interestingly, however, we have found that the murine homologue of *BRCA1* is expressed at highest levels in the mouse in cellular compartments containing rapidly proliferating cells undergoing differentiation, such as are found in the breast during puberty and pregnancy[15, 16]. The positive correlation between *Brca1* expression and cellular proliferation may be explained in part by the observation made in several laboratories, including our own, that the expression of this gene is regulated in a cell cycle-dependent manner with peak steady-state levels of mRNA and protein occurring just prior to and during S-phase[5, 17-19]. The discovery that BRCA1 is phosphorylated in a cell cycle-dependent fashion, as well as the finding that *BRCA1* may be a substrate for certain cyclin-dependent kinases, suggests a possible function for *BRCA1* in cell cycle progression and the regulation of proliferation[5, 20]. This hypothesis is supported by recent reports that *BRCA1* overexpression inhibits cell cycle progression at least in part by upregulating expression of $p21^{WAF1/CIP1}$, a cyclin-dependent kinase inhibitor that contributes to the growth arrest response to DNA damage [21, 22]. Interestingly, recent studies have demonstrated that the BRCA1 protein forms a complex with Rad51[23]. Since Rad51 is required for the proper response to ionizing radiation in yeast, these studies suggest a role for BRCA1 in the response to DNA damage. The observation that BRCA1 is rapidly phosphorylated in response to DNA damage, including that caused by ionizing radiation, strongly supports this model[24, 25]. It is important to note, however, that studies of tumor suppressor genes such as *Rb* and *p53* and have highlighted the fact that proteins in this class typically function in multiple pathways and processes in the cell.

Interestingly, while germline *BRCA1* mutations predispose carriers to adenocarcinoma of the breast, no somatic *BRCA1* mutations have been found in sporadic primary breast cancers. This observation suggests that this molecule may normally protect the breast against carcinogenesis only during specific stages of mammary gland development. Previously, we have analyzed the temporal and spatial pattern of *Brca1* expression during normal mouse embryogenesis, in adult tissues, and during postnatal mammary gland development. These studies support a role for *Brca1* in the regulation of cell proliferation and differentiation in the breast during puberty and pregnancy. We hypothesize that *Brca1* plays a critical role in mammary gland development, and that its function is temporally restricted to particular developmental phases. The focus of this project is to test this hypothesis by using a modified tetracycline-inducible expression system to either induce or abolish *Brca1* expression in transgenic mice during particular developmental stages in a temporally-restricted and breast-specific manner. The goal of this work is therefore to understand more clearly how the loss or mutation of this molecule contributes to carcinogenesis in a developmental-specific manner. This goal will be accomplished by pursuing the following specific aims:

Specicic Aim 1. Develop breast-specific, tetracycline-dependent expression systems to inducibly overexpress or abolish *Brca1* expression in the mammary epithelium *in vivo*. We will develop a modified tetracycline-inducible expression system in order to conditionally express *Brca1* or antisense *Brca1* mRNA in the breast in a temporally-restricted manner. Constructs will be generated in which the

expression of the reverse tetracycline transcriptional activator, rtTA, will be breast-specific and dependent upon the presence of tetracycline. Since both the expression and function of rtTA are tetracycline-dependent, target expression constructs can be developed in which wild-type or mutant *BRCA1* cDNA clones are expressed in a tetracycline-dependent manner by appending them to *Tn10* operator-containing promoters. Additional target expression constructs will be developed in which *Brca1* antisense RNA is expressed in a tetracycline-dependent manner. Transgenic mouse lines will be generated which overexpress the reverse tetracycline transcriptional activator, rtTA, in a breast-specific manner from the mouse mammary tumor virus LTR. Transgenic mouse lines will also be generated which overexpress the reverse tetracycline transcriptional activator, rtTA, in a tetracycline-dependent manner. Finally, transgenic mouse lines will be generated which contain target DNA constructs that direct the tetracycline-dependent expression of wild-type or mutant *Brca1*, or *Brca1* antisense RNA. These transgenic strains should permit the inducible expression of target transgenes during specific stages of mammary gland development.

Specific Aim 2. Inducibly overexpress *Brca1* in the mammary epithelium of transgenic mice during specific developmental stages. The effect of overexpressing *Brca1* during specific stages of mammary gland development will be determined. Bitransgenic mice which express both the rtTA tetracycline-dependent transcriptional activator and a *Brca1* wild-type or mutant transgene driven by a tetracycline-dependent promoter will be derived by mating each of the transgenic strains developed in specific aim 1. *Brca1* overexpression in bitransgenic mice will be induced during specific stages of mammary gland development, including puberty, pregnancy, lactation and regression, by tetracycline treatment during the appropriate developmental window. Glands will be analyzed by morphological and molecular methods for abnormalities in mammary epithelial proliferation, differentiation and development, and for signs of hyperplasia, dysplasia and neoplasia.

Specific Aim 3. Inducibly abolish *Brca1* expression in the mammary epithelium of transgenic mice during specific developmental stages. The effect of abolishing *Brca1* expression during specific stages of mammary gland development will be determined by creating bitransgenic mice which express both the tetracycline-dependent transcriptional activator, rtTA, and a *Brca1* antisense transgene driven by a tetracycline-dependent promoter by mating the transgenic strains developed in specific aim 1. Reduction of *Brca1* expression in bitransgenic mice will be induced during specific stages of mammary gland development as above. Glands will be analyzed by morphological and molecular methods for abnormalities in mammary epithelial proliferation, differentiation and development, and for signs of hyperplasia, dysplasia and neoplasia.

BODY

Technical Objective I: Develop breast-specific, tetracycline-dependent expression systems to inducibly overexpress or abolish BRCA1 expression in mammary epithelial cells.

Task 1: Months 1-12: Construct vectors for expressing rtTA and/or tTA in the mammary epithelium.

In order to create an inducible expression system in mammary epithelial cells *in vivo*, we have constructed several mammary-specific and tetracycline-dependent expression vectors. Specifically, we have made use of the reverse tetracycline-controlled transcriptional activator, rtTA, that fuses the herpes simplex virus VP16 transcription activation domain with a mutant form of the DNA binding domain from the tet repressor of *E. coli*[26]. This transactivator requires tetracycline derivatives for specific DNA binding. Target genes are placed under the control of the tetO regulatory cassette from the tetracycline-resistance operon of Tn10. This system has been documented to rapidly induce gene expression in the presence of tetracycline by up to three orders of magnitude with a low level of basal expression. Moreover, the availability of numerous tetracycline analogs with varied binding affinities, as well as the use of varying concentrations of tetracycline, permits the absolute level of transgene expression to be reproducibly and precisely titrated. As such, this system is ideally suited for the tight control and rapid induction of potentially toxic genes to desired levels of expression.

Plasmid pUHD172-1neo was constructed by Gossen et al. and contains a neomycin-selectable marker as well as sequences encoding the reverse tetracycline-controlled transcriptional activator, rtTA, whose expression is driven by a constitutive CMV promoter/enhancer[26] .

Plasmid pUHD15-1 was also constructed by Gossen et al. and contains a neomycin-selectable marker as well as sequences encoding the tetracycline-controlled transcriptional activator, tTA, whose expression is driven by a constitutive CMV promoter/enhancer[26] .

Plasmid pMMTV.rtTA contains sequences encoding the reverse tetracycline-controlled transcriptional activator, rtTA, whose expression is driven by the mouse mammary tumor virus promoter/enhancer and was constructed by replacing the CMV promoter/enhancer of pUHD172-1neo with the entire MMTV promoter/enhancer long terminal repeat (LTR) containing 2.0 kb of upstream sequence. The MMTV LTR is widely used to obtain mammary-specific expression in transgenic mouse model systems.

Task 2: Months 1-12: Construct vectors for expressing rtTA and/or tTA in a tetracycline-dependent manner.

Since constitutive expression of rtTA has been reported to be detrimental in some cell types, we have created a modification of the tetracycline-dependent expression system by replacing the constitutive CMV-derived promoter/enhancer driving rtTA expression in pUHD172-1neo, with the tet regulatory sequences (tetO) from Tn10, to create the autoregulatory plasmid, pTetO.rtTA (Fig. 1A). A similar approach has been successfully taken by others with the original tTA tetracycline-repressible transcriptional activator[27]. As a result, in this system the expression of the transcriptional activator, rtTA, is itself induced by the addition of tetracycline, and subsequently induces the target gene in a tetracycline-dependent manner. As a result, induction occurs at two different regulatory levels - the expression of the rtTA activator, and the binding and activation of the target promoter by rtTA.

Task 3: Months 1-12: Construct target vectors expressing wild type and mutant forms of BRCA1.

In order to permit the expression of target genes of interest in a tetracycline-dependent manner we have constructed a tetracycline-incucible expression vector, pTet-Target.Puro, that contains both a tetracycline-inducible promoter driving the expression of a target gene, and a puromycin-selectable marker (Fig. 1D). The puromycin-resistance gene, whose expression is driven by the PGK promoter, was obtained from the

retroviral vector pLZRS as a ClaI-BspHI fragment, blunted with the Klenow fragment of DNA polymerase, and cloned in the NotI restriction site of pTet-Splice (Life Sciences).

In order to permit the inducible expression of wild-type BRCA1 in mammary epithelial cells in a tetracycline-dependent manner, a full-length cDNA encoding wild-type BRCA1 was subcloned into the HindIII site of pTet-Target.Puro to generate pTet.BRCA1.wt.

In order to permit the inducible expression of mutant forms of BRCA1 in mammary epithelial cells in a tetracycline-dependent manner, a cDNA clone encoding BRCA1 truncated at the carboxy-terminal ApaI restriction site was subcloned into the HindIII site of pTet-Target.Puro to generate pTet.BRCA1.ApaI. In addition, a cDNA clone encoding the naturally occurring mutant of BRCA1 C64G was constructed. This mutation contains a point mutation in the RING finger domain of BRCA1 that has been found to cosegregate with breast and ovarian cancer in BRCA1 families. This point mutation was created by PCR site-directed mutagenesis using overlapping PCR primers containing complementary mutational changes at C64. The resulting HindIII-BglI fragment containing the mutant region was subloned into wild-type BRCA1. The full-length HindIII fragment containing the mutant BRCA1 was then subcloned into the HindIII site of pTet-Target.Puro to generate pTet.BRCA1.C64G.

***Task 4:** Months 1-12: Construct target vectors expressing BRCA1 antisense RNA.*

In order to permit the inducible expression of BRCA1 antisense RNA in mammary epithelial cells in a tetracycline-dependent manner, the target construct pTet.BRCA1.AS was generated. A 400 bp region containing the 5' region of mouse BRCA1 was amplified by RT-PCR from first-strand breast cDNA. This region spans the translation initiation codon of BRCA1. This 400 bp PCR fragment was sequenced on both strands to verify that it contained wild-type sequence and was then subcloned into the HindIII-EcoRV site of pTet-Target.Puro in the antisense orientation to generate pTet.BRCA1.AS. As a control, the same 400 bp fragment was subcloned into pTet-Target.Puro in the sense orientation to generate pTet.BRCA1.S.

In order to test the ability of the expression vectors described above to permit tetracycline-dependent inducible expression in mammary epithelial cells *in vivo*, we have used these constructs to generate a test inducible expression system in mammary epithelial cells *in vitro*. We have stably transfected pTetO.rtTA, which contains a neomycin-selectable marker, into HC11 mammary epithelial cells to generate the



Fig. 1: Generation of a tetracycline-inducible expression system in mammary epithelial cells

mammary epithelial cell clone, HC11.rtTA (Fig. 1A, B). This clone inducibly expresses the rtTA tetracycline-regulated transcriptional activator in the presence of tetracycline (Fig. 1B). In addition, we

have demonstrated that the HC11.rtTA clone faithfully differentiates in response to the lactogenic hormones, prolactin, insulin and hydocortisone in the presence or absence of tetracycline, indicating that overexpression of rtTA does not interfere with the process of differentiation (Fig. 1C). This result suggests that the inducible expression of rtTA in mammary epithelial cells represents a suitable system for determining the effect of *Brca1* on mammary epithelial proliferation and differentiation.

In order to test the function of the tetracycline-incucible expression vector, pTet-Target.Puro, that contains both a tetracycline-inducible promoter driving the expression of a target gene, and a puromycin-selectable marker, pTetO-Target.Puro was stably transfected into HC11.rtTA (Fig. 1D). Puromycin-resistant clones obtained following transfection of HC11.rtTA cells with this construct express high levels of mRNA for the puromycin-resistance gene (Fig. 1E). No spontaneously puromycin-resistant clones have been detected following puromycin selection of untransfected HC11.rtTA cells.

In order to test the ability of the tetracycline-dependent transcriptional activator, rtTA, to induce the expression of the tetracycline-dependent target gene in the pTet-Target.Puro expression vector, the parental HC11.rtTA cell line has been stably transfected with pTet.BRCA1.AS. Puromycin-resistant clones were demonstrated to inducibly express *Brca1* antisense RNA in the presence of



Fig. 2: Graded inducible expression of *Brca2* antisense RNA

doxycycline (Fig. 2B). Induction occurs rapidly, is stable, and occurs in a graded fashion dependent on doxycycline concentration (Fig. 2C). Clones expressing antisense RNA are currently being assayed for their ability to specifically downregulate *Brca1* expression.

Technical Objective II: Create transgenic mice overexpressing BRCA1 or BRCA1 antisense in the mammary epithelium.

Task 1: *Months 8-24: Create and identify transgenic lines of mice expressing rtTA and/or tTA in the mammary epithelium.*

In order to test the hypothesis that *Brca1* plays a role in the normal control of mammary epithelial proliferation and differentiation *in vivo*, *Brca1* will be overexpressed in the mammary glands of transgenic mice. Given concerns regarding possible toxic effects of *Brca1* overexpression, we have chosen to conditionally overexpress *Brca1 in vivo* using a tetracycline regulatory system. We have constructed a mammalian expression vector, pMMTV.rtTA, in which expression of the tetracycline-inducible transactivator, rtTA, is driven by the promoter/enhancer of the MMTV LTR. In order to generate transgenic mice harboring this construct, purified DNA containing the pMMTV-rtTA transgene was injected into fertilized oocytes harvested from superovulated FVB female mice. Two founder mice,

designated MTA and MTB, were identified that harbored the transgene in tail-derived DNA and that passed this transgene to offspring in a Mendelian fashion. Northern hybridization analysis of tissues derived from progeny of the MTA and MTB lines of mice revealed high levels of breast-specific rtTA expression in female virgin animals (Fig. 3). Expression was not detected in other tissues of female mice tested, and was expressed at markedly lower levels in the seminal vesicles of male mice, indicating that rtTA expression is breast-specific.

In order to create transgenic lines of mice that express rtTA in a tetracycline-dependent manner, purified DNA containing the pTetO.rtTA transgene was injected into fertilized oocytes harvested from superovulated FVB female mice. Two founder mice, designated TTB and TTE, were identified that harbored the transgene in tail-derived DNA and that passed this transgene to offspring in a Mendelian fashion. Northern hybridization analysis of tissues derived from progeny of the TTB and TTE lines of mice failed to reveal detectable levels of rtTA expression in the mammary glands of female virgin animals (Fig. 3). Low levels of expression of rtTA were detected in TTB and TTE animals in the thymus, kidney and spleen. The rtTA expression pattern of these animals is continuing to be characterized.

We have also constructed mammalian expression vectors, pTetO-LacZ, in which expression of the *LacZ* gene is driven by the tetO-containing promoter cassette, in order to serve as an indicator strain to permit the quantitative characterization of the rtTA/tetO-target bitransgenic expression system created in this proposal. This construct should permit the inducible expression of *LacZ* in response to tetracycline in cells expressing the rtTA transcriptional activator. Using an approach similar to that described above this



Fig. 3: Bitransgenic system for inducibly overexpressing genes in the breast of transgenic mice

construct, which also contains SV40 splicing and polyadenylation signals, has been used to generate transgenic mice in the FVB background. Founder animals have been identified that pass the pTetO-LacZ transgene to their offspring in a Mendelian fashion.

In order to determine whether this transgenic system will permit inducible transgene expression in the breast in response to tetracycline analogs, MMTV-rtTA transgenic mice were mated to TetO-LacZ mice and bitransgenic mice were identified. Wild-type (non-transgenic) and bitransgenic mice were treated with doxycycline. Breast tissue from wild-type and bitransgenic mice was harvested after 48 hours of treatment with doxycycline, as was breast tissue from a bitransgenic littermate that had not been treated with doxycycline. RNA was prepared from these three tissue samples and steady-state levels of *rtTA* and *LacZ* mRNA expression were assessed by Northern hybridization (Fig. 3B). As expected, bitransgenic animals expressed *rtTA* at similar levels in the presence and absence of doxycycline, whereas the *LacZ*

target mRNA was only expressed in bitransgenic animals treated with doxycycline. No *LacZ* mRNA was detected either in wild-type animals, or in untreated bitransgenic animals.

In order to quantitate the level of lacZ protein expression in the induced and uninduced states, beta-galactosidase assays were performed on protein extracts made from each of the harvested breast tissues (Fig. 3C). As expected, no beta-galactosidase activity was detected in extracts prepared from non-transgenic breast tissue. Also as expected, abundant beta-galactosidase activity was present in extracts prepared from bitransgenic animals treated with doxycycline for 48 hours. Impressively, no beta-galactosidase activity was detected in protein extracts prepared from untreated bitransgenic animals. Based on the lower limits of detection for this assay, we estimate that the minimum induction of transgene expression observed in this experiment is at least 700-fold, and that the actual level of induction may be 1 or 2 logs higher. Our estimates of the minimum level of induction are comparable to that observed in a related system making use of the tTA tetracycline-dependent repressor, rather than the rtTA tetracycline-dependent transactivator[28]. Our results suggest that the MMTV-rtTA/TetO-transgene system that we have generated will permit the rapid and breast-specific induction of transgene expression at high levels, in combination with extremely low levels of expression in the uninduced state. Notably, this system permits the modulation of transgene expression levels both by varying the concentration of doxycycline and by varying the tetracycline derivative used. These properties are ideal for determining the effects of a potentially toxic transgene on specific stages of mammary gland development, and for obtaining levels of transgene expression that are in the physiological range.

The TetO.rtTA transgenic lines of mice, TTB and TTE, will also be mated to TetO-LacZ mice in order to quantitate the pattern and extent of tetracycline inducibility of rtTA and of target genes in these bitransgenic animals.

Task 2: *Months 8-24: Create and identify transgenic lines of mice expressing wild type and mutant forms of BRCA1 in a tetracycline-dependent manner.*

As described above, we have constructed a mammalian expression vector, pTetO.BRCA1, in which expression of *BRCA1* is driven by the tetO-containing promoter cassette. This constructs should permit the inducible expression of *BRCA1* in response to tetracycline in cells expressing the rtTA transcriptional activator. Using an approach similar to that described above this construct, which also contains SV40 splicing and polyadenylation signals, has been used to generate transgenic mice in the FVB background. To date, 1 founder animal has been identified that passes the pTetO-BRCA1 transgene to its offspring in a Mendelian fashion. This line of mice will be characterized as described below.

Task 3: *Months 8-24: Create and identify transgenic lines of mice expressing BRCA1 antisense RNA in a tetracycline-dependent manner.*

The completion of this task is pending at the current time. The antisense constructs described above will first be tested for their ability to specifically reduce the expression of BRCA1 protein using the HC11 *in vitro* test system that we have generated. If these experiments are successful, a DNA fragment containing the pTetO-BRCA1.AS expression cassette will be injected into fertilized oocytes harvested from superovulated FVB female mice, using an approach similar to that described above. Founder mice will be identified that harbor the transgene in tail-derived DNA and that pass this transgene to offspring in a Mendelian fashion.

Task 4: *Months 8-24: Breed transgenic lines of mice to create a bitransgenic line of mice expressing wild type and mutant forms of BRCA1 in the breast in a tetracycline-dependent manner.*

The completion of this task is pending at the current time. MMTV-rtTA transgenic mice identified above will be mated to offspring of the TetO-BRCA1 transgenic line described above. Bitransgenic offspring will be identified by PCR. The expression of BRCA1 will be induced in bitransgenic animals by treatment with doxycycline. Breast tissue will be harvested from treated and untreated bitransgenic animals as well as control non-transgenic animals. BRCA1 expression in the breast will be assayed at the mRNA level by Northern hybridization and RNase protection, and at the protein level by immunoblotting. Additional founder animals passing the pTetO-BRCA1 transgene to their offspring will also be characterized.

Task 5: *Months 8-24: Breed transgenic lines of mice to create a bitransgenic line of mice expressing BRCA1 antisense in the breast in a tetracycline-dependent manner.*

The completion of this task will depend on the successful completion of Task 3 in which transgenic lines of mice are created that express BRCA1 antisense RNA in a tetracycline-dependent manner.

Technical Objective III: Determine the effect of inducibly overexpressing BRCA1 in the mammary epithelium of transgenic mice during specific developmental stages.

Task 1: *Months 24-48: Analyze the phenotype of inducibly overexpressing wild type BRCA1 in the mammary epithelium during specific developmental stages.*

The completion of this task will depend on the successful completion of tasks described above in which bitransgenic lines of mice are generated that express wild type forms of BRCA1 in the breast in a tetracycline-dependent manner.

Task 2: *Months 24-48: Analyze the phenotype of inducibly overexpressing mutant forms of BRCA1 in the mammary epithelium during specific developmental stages.*

The completion of this task will depend on the successful completion of tasks described above in which bitransgenic lines of mice are generated that express mutant forms of BRCA1 in the breast in a tetracycline-dependent manner.

Technical Objective IV: Determine the effect of inducibly abolishing BRCA1 expression in the mammary epithelium of transgenic mice during specific developmental stages.

Task 1: *Months 24-48: Analyze the phenotype of inducibly abolishing BRCA1 expression in the mammary epithelium during specific developmental stages.*

The completion of this task will depend on the successful completion of tasks described above in which bitransgenic lines of mice are generated that express BRCA1 antisense RNA in the breast in a tetracycline-dependent manner and that result in the specific reduction in BRCA1 protein in mammary epithelial cells.

CONCLUSIONS

A number of important milestones have been accomplished during the first year of this project. We have constructed a variety of plasmid vectors for expressing rtTA in the mammary epithelium in a tetracycline-dependent or tetracycline-independent manner. We have also created target vectors for expressing wild-type and mutant forms of BRCA1, as well as target vectors for expressing BRCA1 antisense RNA. These vectors have been used to create four transgenic lines of mice containing the TetO-rtTA, MMTV-rtTA, TetO-LacZ and TetO-BRCA1 expression cassettes. Experiments to date demonstrate that the MMTV-rtTA transgenic line of mice express the tetracycline-dependent reverse transcriptional activator, rtTA, at high levels and in a breast-specific manner. The creation of bitransgenic MMTV-rtTA/TetO-LacZ mice has permitted the initial analysis of the utility of this inducible transgenic system. These results strongly suggest that this system is capable of inducing target gene expression to high levels in a breast-specific fashion in response to induction with tetracycline derivatives. In addition, this system demonstrates extremely low levels of basal expression.

The studies described above demonstrate that we have made significant progress towards the completion of the specific aims of this project during the first year. All technical objectives that were predicted to be complete by the end of the first year of this project have been successfully comleted. In addition, substantial progress has also been made on a number of other technical objectives slated to be completed during the first two years of this project. These findings suggest that the experiments proposed can be executed in a timely fashion to answer important scientific questions regarding the function of the breast cancer susceptibility gene, BRCA1, in the mammary gland.

REFERENCES

1. Newman B, Austin MA, Lee M and King M-C. Inheritance of breast cancer: evidence for autosomal dominant transmission in high risk families. *Proceedings of the National Academy of Sciences*, **85**:1-5, 1988.
2. Claus EB, Risch N and Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. *American Journal of Human Genetics*, **48**:232-241, 1991.
3. Easton DF, Bishop DT, Ford D and Crockford GP. The Breast Cancer Linkage consortium. Genetic linkage analysis in familial breast and ovarian cancer. Results from 214 families. *American Journal of Human Genetics*, **52**:678-701, 1993.
4. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S and al. e. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science*, **266**:66-71, 1994.
5. Chen Y, Farmer A, Chen C-F, Jones D, Chen P-L and Lee W-H. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. *Cancer Research*, **56**:3168-3172, 1996.
6. Koonin E, Altschul S and Bork P. Functional motifs (letter). *Nature Genetics*, **13**:266-267, 1996.
7. Bork P, Hofmann K, Bucher P, Neuwald A, Altschul S and Koonin E. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. *FASEB Journal*, **11**, 1997.
8. Chapman M and Verma I. Transcriptional activation by BRCA1. *Nature*, **382**:678-679, 1996.
9. Callebaut I and Mornon J-P. From BRCA1 to RAP1 : a widespread BRCT module closely associated with DNA repair. *FEBS Letters*, **400**:25-30, 1997.
10. Monteiro A, August A and Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. *Proceedings of the National Academy of Sciences USA*, **93**:13595-13599, 1996.
11. Smith SA, Easton DG, Evans DGR and Ponder BAJ. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. *Nature Genetics*, **2**:128-131, 1992.
12. Rao VN, Shao NS, Ahmad M and Reddy RSP. Antisense RNA to the putative tumor suppressor gene BRCA1 tranforms mouse fibroblasts. *Oncogene*, **12**:523-528, 1996.
13. Thompson ME, Jensen RA, Obermiller PS, Page DL and Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. *Nature Genetics*, **9**:444-450, 1995.
14. Holt J, Thompson M, Szabo C, Robinson-Benion C, Arteaga C, King M-C and Jensen R. Growth retardation and tumour inhibition by BRCA1. *Nature Genetics*, **12**:298-302, 1996.
15. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin G-Y, Abel KJ, Weber BL and Chodosh LA. The developmental pattern of *Brca1* expression implies a role in differentiation of the breast and other tissues. *Nature Genetics*, **11**:17-26, 1995.
16. Lane TF, Deng CX, Elson A, Lyu MS, Kozak CA and Leder P. Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. *Genes Dev.*, **9**:2712-2722, 1995.
17. Rajan JV, Wang M, Marquis ST and Chodosh LA. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. *Proceedings of the National Academy of Science*, **93**:13078-13083, 1996.
18. Vaughn J, Davis P, Jarboe M, Huper G, Evans A, Wiseman R, Berchuck A, Iglehart J, Futreal P and Marks J. BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. *Cell Growth & Differentiation*, **7**:711-715, 1996.
19. Gudas J, Li T, Nguyen H, Jensen D, Rauscher FI and Cowan K. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. *Cell Growth & Differentiation*, **7**:717-7123, 1996.
20. Ruffner H and Verma I. BRCA1 is a cell cycle-regulated uclear phosphoprotein. *Proceedings of the National Academy of Sciences USA*, **94**:7138-7143, 1997.
21. Somasundaram K, Zhang H, Zeng Y-X, Houvras Y, Peng Y, Zhang H, Wu G, Licht J, Weber B and El-Deiry W. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21. *Nature*, **389**:187-190,

22. El-Deiry W, Tokino T, Velculescu V, Levy D, Parsons R, Trent J, Lin D, Mercer W, Kinzler K and Vogelstein B. WAF1 is a potential mediator of p53 tumor suppression. *Cell*, **75**:817-825, 1993.
23. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T and Livingston D. Association of BRCA1 with Rad51 in mitotic and meiotic cells. *Cell*, **88**:265-275, 1997.
24. Thomas J, Smith M, Tonkinson J, Rubinfeld B and Polakis P. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. *Cell Growth & Differentiation*, **8**:801-809, 1997.
25. Scully R, Chen J, Ochs R, Keegan K, Hoekstra M, Feunteun J and LIvingston D. Dynamic Changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. *Cell*, **90**:425-435, 1997.
26. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W and Bujard H. Transcriptional activation by tetracyclines in mammalian cells. *Science*, **268**:1766-1769, 1995.
27. Shockett P, Difilippantonio M, Hellman N and Schatz D. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. *Proceedings of the National Academy of Sciences USA*, **92**:6522-6526, 1995.
28. Hennighausen L, Wall RJ, Tillmann U, Li M and Furth P. Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and the tetracycline responsive system. *Journal of Cellular Biochemistry*, **59**:463-472, 1995.

DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

Received 7/23/2001

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports. Request the limited distribution statement for reports on the enclosed list be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

Encl